ListarArtículos (Bioquímica Médica y Biología Molecular e Inmunología) por materia "PD-L1"
Mostrando ítems 1-3 de 3
-
Artículo
NK cells and solid tumors therapeutic potential and persisting obstacles
(BMC, 2022-11-01)Natural killer (NK) cells, which are innate lymphocytes endowed with potent cytotoxic activity, have recently attracted ...
-
Artículo
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
(BMC, 2023)Background: We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and ...
-
Artículo
Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
(MDPI, 2021-10-29)The PANGEA-Breast trial evaluated a new chemo-immunotherapeutic combination that would synergistically induce long-term ...